|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide ... (TMC 435) (Company: Janssen Pharmaceutical) 2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim) 3. Asunaprevir ... Forecast (Chapter 7) 1. Simeprevir (TMC 435) 2. Faldaprevir (BI 201335) (Boerhinger Ingelheim) 3. Asunaprevir (BMS ... KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen Analyzing the Hepatitis C Market Landscape After more than a decade of limited treatment options, the hepatitis C (HCV) market is on the cusp of a treatment revolution. In 2011, protease inhibitors-Incivek (telaprevir; Vertex) and Victrelis (boceprevir; ... Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the ... Therapy Class Overview : Hepatitis C Virus Infection Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead’s ... Therapeutic Class Report Overview : Hepatitis C Virus Infection The launch of Protease inhibitors’ (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians ... |